Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

Balancing MS Relapse Risk With Personalized Therapy Decisions: Gabrielle Macaron, MD

Articles

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

Using AI to Assist in Identifying Cardiovascular Risk in Patients With Migraine

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care. [WATCH TIME: 5 minutes]

Modernizing Multiple Sclerosis Care With Digital Tools and Holistic Clinical Approaches: Agne Straukiene, MD

Associate professor of neurology at Emory University and co-director of the Emory ALS Center.

Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]

Clinicians Express Growing Optimism in ALS Research and Treatment Advancements

Chief Scientific Officer, Dravet Syndrome Foundation

Veronica Hood, PhD, chief scientific officer at the Dravet Syndrome Foundation, discussed the evolving care landscape of Dravet syndrome, highlighting breakthroughs in precision medicine and promising new therapies for patients.

The Changing Landscape of Dravet Syndrome 

Experts discussed the ongoing importance of awareness, funding, and early diagnosis in amyotrophic lateral sclerosis, welcoming the return of the well-known Ice Bucket Challenge. [WATCH TIME: 5 minutes]

Reviving ALS Awareness Campaigns to Reaffirm Support for the Patient Community

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Rapid Readout: Clinical Updates in Multiple Sclerosis From CMSC 2020

Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

The Multidisciplinary Theme of CMSC 2020

Progressive MS: The 2020 Whitaker Lecture

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

Primary Results From the ENSEMBLE PLUS Study

Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

CMSC Data Release: Abstract DXT58 and MS Risk Reduction

Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The Special Reports video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases. It also includes the RX Reports bonus series, which focuses on new therapeutics and FDA approvals.

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Newsletter